CH Biotech R&D Balance Sheet Health
Financial Health criteria checks 6/6
CH Biotech R&D has a total shareholder equity of NT$2.5B and total debt of NT$575.6M, which brings its debt-to-equity ratio to 22.8%. Its total assets and total liabilities are NT$3.6B and NT$1.1B respectively. CH Biotech R&D's EBIT is NT$565.9M making its interest coverage ratio -1373.4. It has cash and short-term investments of NT$943.0M.
Key information
22.8%
Debt to equity ratio
NT$575.60m
Debt
| Interest coverage ratio | -1373.4x |
| Cash | NT$943.00m |
| Equity | NT$2.52b |
| Total liabilities | NT$1.13b |
| Total assets | NT$3.65b |
Recent financial health updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05
Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15
Recent updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns
Mar 18Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 09Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture
Jan 11Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield
Nov 24Financial Position Analysis
Short Term Liabilities: 6534's short term assets (NT$1.2B) exceed its short term liabilities (NT$882.3M).
Long Term Liabilities: 6534's short term assets (NT$1.2B) exceed its long term liabilities (NT$246.7M).
Debt to Equity History and Analysis
Debt Level: 6534 has more cash than its total debt.
Reducing Debt: 6534's debt to equity ratio has reduced from 85.9% to 22.8% over the past 5 years.
Debt Coverage: 6534's debt is well covered by operating cash flow (114.5%).
Interest Coverage: 6534 earns more interest than it pays, so coverage of interest payments is not a concern.